Literature DB >> 12691629

The role of nonconventional magnetic resonance imaging techniques in demyelinating disorders.

Francesca Bagnato1, Joseph A Frank.   

Abstract

The use of nonconventional magnetic resonance imaging techniques (eg, magnetization transfer, magnetic resonance spectroscopy, and diffusion weighted imaging) allows for an accurate characterization of lesions as compared with conventional or standard approaches in demyelinating diseases. Magnetization transfer, magnetic resonance spectroscopy, and diffusion weighted imaging have revolutionized our understanding of demyelinating diseases because these techniques have been used to identify pathologic changes of normal-appearing brain tissue and characterize the differences in lesions. Metrics derived from these methods correlate with clinical disability and provide more accurate tools for monitoring disease activity and treatment effect over time. Quantitative T1 and T2 relaxation time maps provide additional information on demyelinating diseases, allowing for the evaluation of myelin water and distribution of water within tissues. Finally, the measurement of central nervous system atrophy has become a valuable element in determining the course of multiple sclerosis.

Entities:  

Mesh:

Year:  2003        PMID: 12691629     DOI: 10.1007/s11910-003-0084-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   6.030


  48 in total

Review 1.  Magnetization transfer imaging of the spinal cord and the optic nerve in patients with multiple sclerosis.

Authors:  J H van Waesberghe; F Barkhof
Journal:  Neurology       Date:  1999       Impact factor: 9.910

2.  Diffusion tensor MR imaging of the human brain.

Authors:  C Pierpaoli; P Jezzard; P J Basser; A Barnett; G Di Chiro
Journal:  Radiology       Date:  1996-12       Impact factor: 11.105

3.  Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis.

Authors:  F Fazekas; S Ropele; C Enzinger; T Seifert; S Strasser-Fuchs
Journal:  Mult Scler       Date:  2002-12       Impact factor: 6.312

4.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

5.  In vivo visualization of myelin water in brain by magnetic resonance.

Authors:  A MacKay; K Whittall; J Adler; D Li; D Paty; D Graeb
Journal:  Magn Reson Med       Date:  1994-06       Impact factor: 4.668

6.  Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression.

Authors:  N A Losseff; S L Webb; J I O'Riordan; R Page; L Wang; G J Barker; P S Tofts; W I McDonald; D H Miller; A J Thompson
Journal:  Brain       Date:  1996-06       Impact factor: 13.501

7.  Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal-appearing white matter.

Authors:  Alexander C Guo; James R MacFall; James M Provenzale
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

8.  Diffusion of water in large demyelinating lesions: a follow-up study.

Authors:  A Castriota-Scanderbeg; U Sabatini; F Fasano; R Floris; L Fraracci; M Di Mario; U Nocentini; C Caltagirone
Journal:  Neuroradiology       Date:  2002-06-13       Impact factor: 2.804

9.  MR identification of white matter abnormalities in multiple sclerosis: a comparison between 1.5 T and 4 T.

Authors:  M D Keiper; R I Grossman; J A Hirsch; L Bolinger; I L Ott; L J Mannon; C P Langlotz; D L Kolson
Journal:  AJNR Am J Neuroradiol       Date:  1998-09       Impact factor: 3.825

10.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations.

Authors:  P A Brex; G J Parker; S M Leary; P D Molyneux; G J Barker; C A Davie; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.